fda warning compounded semaglutide safety 2024 2025 Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines Compounded "semaglutide" is not FDA-approved

We present a 37-year-old woman who was prescribed semaglutide for diabetes and weight loss who subsequently experienced significant weight reduction and rapid glycemic control over three months

Soaring use of these medications for weight loss is shifting demand, including for packaging manufacturers that serve pharma and food customers

Medicaid Services proposed to expand Medicare Part D and Medicaid to cover weight loss drugs

Noom issued a call for public support of a new petition demanding affordable choices and fair pricing for GLP-1 weight-loss medications

Historically, they have been used mainly to treat type-2 diabetes